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Abstract
Background: Rapamycin is an effective immunosuppressant widely used to maintain the renal
allograft in pediatric patients. Linear growth may be adversely affected in young children since
rapamycin has potent anti-proliferative and anti-angiogenic properties.
Methods: Weanling three week old rats were given rapamycin at 2.5 mg/kg daily by gavage for 2
or 4 weeks and compared to a Control group given equivalent amount of saline. Morphometric
measurements and biochemical determinations for serum calcium, phosphate, iPTH, urea nitrogen,
creatinine and insulin-growth factor I (IGF-I) were obtained. Histomorphometric analysis of the
growth plate cartilage, in-situ hybridization experiments and immunohistochemical studies for
various proteins were performed to evaluate for chondrocyte proliferation, chondrocyte
differentiation and chondro/osteoclastic resorption.
Results: At the end of the 2 weeks, body and tibia length measurements were shorter after
rapamycin therapy associated with an enlargement of the hypertrophic zone in the growth plate
cartilage. There was a decrease in chondrocyte proliferation assessed by histone-4 and mammalian
target of rapamycin (mTOR) expression. A reduction in parathyroid hormone/parathyroid hormone
related peptide (PTH/PTHrP) and an increase in Indian hedgehog (Ihh) expression may explain in part,
the increase number of hypertrophic chondrocytes. The number of TRAP positive multinucleated
chondro/osteoclasts declined in the chondro-osseous junction with a decrease in the receptor
activator of nuclear factor kappa β ligand (RANKL) and vascular endothelial growth factor (VEGF)
expression. Although body and tibial length remained short after 4 weeks of rapamycin, changes in
the expression of chondrocyte proliferation, chondrocyte differentiation and chondro/osteoclastic
resorption which were significant after 2 weeks of rapamycin improved at the end of 4 weeks.
Conclusion:  When given to young rats, 2 weeks of rapamycin significantly decreased
endochondral bone growth. No catch-up growth was demonstrated at the end of 4 weeks,
although markers of chondrocyte proliferation and differentiation improved. Clinical studies need
to be done to evaluate these changes in growing children.
Background
Rapamycin is a powerful immunosuppressant widely
used in children to maintain the renal allograft. Studies
have shown that rapamycin decreases cell proliferation by
inhibition of the mammalian target of rapamycin
(mTOR), a key regulator in cell growth. In addition,
rapamycin has been demonstrated to exert anti-ang-
iogenic properties to control tumor growth by reduction
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in vascular endothelial growth factor (VEGF) expression
[1,2]. Due to its anti-proliferative effects, long-term
rapamycin therapy may have adverse effects on linear
growth in young children.
Investigators have reported that bone length decreased in
young rats with normal renal function treated with
rapamycin at 2 mg/kg daily for 14 days accompanied by
alterations in growth plate architecture and lower
chondrocyte proliferation assessed by bromodeoxyurid-
ine (BrDU) incorporation [3,4]. Changes in trabecular
bone modeling and remodeling with decrease in body
length have been demonstrated in 10 week old rats after 2
weeks of rapamycin [3]. In contrast, Joffe and coworkers
showed that a higher dose of rapamycin at 2.5 mg/kg per
day for 14 days transiently lowered serum osteocalcin and
calcitriol levels but it did not affect trabecular bone vol-
ume or bone formation rate [5]. Rapamycin inhibited
osteoclast function, lessened bone resorption, decreased
osteoblast proliferation and enhanced osteoblast differen-
tiation in various in-vitro experiments [6-8].
Since rapamycin is now a standard immunosuppressant
used to maintain an organ transplant in children, linear
growth may be affected if rapamycin is administered long-
term to young and growing patients. The aim of the cur-
rent study is to assess the short and long-term effects of
rapamycin on endochondral bone growth in young rats
with normal renal function using markers of chondrocyte
proliferation, chondrocyte differentiation, chondroclast/
osteoclastic resorption and angiogenesis in the tibial
growth plate.
Methods
Twenty six male, 3 week old Sprague-Dawley rats with
mean weight of 47 ± 4 grams, mean length of 20 ± 1 cm,
were obtained from Harlan Laboratories (Indianapolis,
IN), housed in individual cages at constant temperature
with free access to drinking water. These are the approxi-
mate age comparisons between a rat and a child: a three
week old weanling rat may be comparable to an infant
and a rat between 5 to 7 weeks of age may approximate
the age of a child. After 24 hours of acclimatization, the
rats were randomly assigned to two groups: Rapamycin, N
= 13, or Control, N = 13. Rapamycin was given at 2.5 mg/
kg daily by gavage route and equal amount of saline was
given to the Control group. The dose of rapamycin was
based on previous published studies that demonstrated
significant effects on body growth [4] and the length of
treatment was adapted from our previous experiments
that showed changes in the growth plate after 10 days of
treatment [9]. Rapamycin and saline were given either for
2 weeks (Rapamycin-2 wks, N = 6; Control-2 wks, N = 6)
or 4 weeks (Rapamycin-4 wks, N = 7; Control-4 wks, N =
7). All procedures were reviewed and approved by the
Research Animal Resource Center at the University of Wis-
consin and conducted in accordance with the accepted
standards of humane animal care.
Rapamycin can lower oral intake which may subsequently
affect growth [10]. To ensure equivalent caloric intake in
all animals, the Rapamycin group was pair-fed to the Con-
trol animals by providing the amount of food each day to
Control that had been consumed the previous day by the
Rapamycin treated rats using a standard rodent diet
(23.4% protein, 0.6% calcium, 0.6% phosphate) (Purina
Mills, Indianapolis, IN).
Body weight was obtained weekly and body length was
measured at the start and at the end of the 2 weeks or 4
weeks study period under sedation by measuring the dis-
tance from the tip of the nose to the end of the tail. At the
end of the study period, the rats were anesthetized, killed
by exsanguination and underwent trans-cardiac perfusion
with 4% paraformaldehyde in phosphate buffered saline.
Blood was obtained for determinations of serum calcium,
creatinine, phosphate, urea nitrogen, parathyroid hor-
mone (PTH) and insulin-like growth factor-I. Both tibiae
from each animal were obtained and tibial length was
measured between the proximal and distal articular sur-
faces using a caliper. Triplicate measurements were
obtained for each bone, and the average of these determi-
nations was taken to represent overall tibial length. Bones
were decalcified in 15% ethylenediamine tetra-acetic acid
in phosphate buffered saline, pH 7.4, at 4°C for approxi-
mately two weeks and embedded in paraffin. Five
micrometer sections of bone were obtained for morpho-
metric analysis, in-situ hybridization and immunohisto-
chemistry studies.
Serum biochemical determinations
Serum was obtained by centrifugation and samples were
stored at -80°C until assays are done. Serum urea nitro-
gen, creatinine, calcium, and phosphate levels were meas-
ured using standard laboratory methods. Parathyroid
hormone levels were measured using the Rat Bioactive
Intact PTH ELISA assay kit (Immutopics, San Clemente,
CA). IGF-I levels were measured using the Rat IGF-I ELISA
assay kit (Diagnostic Systems Laboratories Inc, Webster,
TX).
Growth plate morphometry
The proximal growth plate of the tibia was selected for the
experiments due to its fast growth [11]. For morphometric
analysis, three 5-μm sections of bone were obtained from
each tibia and stained with hematoxylin and eosin. Sec-
tions were viewed by light microscopy at 25× and images
were captured onto a computer monitor. The total width
of the growth plate cartilage at the proximal end of each
tibia was measured at equally spaced intervals along anBMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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axis oriented 90° to the transverse plane of the growth
plate and parallel to the longitudinal axis of the bone
using an image-analysis software (Elektronik 200, Kon-
tron Instruments, Ltd., Hallbergmoos, Germany) [9]. At
least ten measurements were obtained from each epiphy-
seal growth plate. The width of the zones occupied by
hypertrophic and proliferative chondrocytes was meas-
ured by the same method and the values are expressed as
a ratio of the hypertrophic or proliferative zone to the
total growth plate width.
In-situ hybridization (radioactive)
For in-situ and immunohistochemistry experiments, indi-
vidual sections of bone obtained from rats in each study
group were mounted together on individual glass slides to
permit valid side-by-side comparisons among samples
from each group and to minimize differences that could
be attributed to slide-to-slide variation during the speci-
men processing and development. Approximately 70–80
slides are included in each experiment.
In-situ hybridization was performed using methods
described elsewhere [9]. Briefly, 35S-labeled sense and
antisense riboprobes were generated encoding mouse
MMP-9/gelatinase B (provided by Drs. G.V. Segre and K.
Lee, MGH, Boston, MA) and rat vascular endothelial growth
factor (provided by Dr. Zena Werb, University of Califor-
nia, San Francisco, CA) and labeled to a specific activity of
1–2 × 109 cpm/μg using the Gemini transcription kit
(Promega Corp, Madison, WI). After hybridization and
post-hybridization washing, the slides were exposed to x-
ray film (Kodak Scientific Imaging Systems, Rochester,
New York) overnight, and emulsion autoradiography was
done using NTB-2 (Eastman Kodak, Rochester, New York)
at 4°C.
Slides were viewed at 100× under bright field microscopy
and the number of silver grains overlying each chondro-
cyte profile was counted using an image analysis system
(Kontron Instruments, Hallbergmoos, Germany) [9]. In
each specimen, fifty to sixty cell profiles (chondrocytes)
were assessed in the layer of chondrocytes where mRNA
was expressed and the results represent the average of
these measurements. Data are expressed as the number of
silver grains/1000 μm2 of cell profile. To quantify gelati-
nase B/MMP-9 expression, the slides were viewed at 65×
and the area with the silver grains was measured and
expressed as percentage of the total area in the chondro-
osseous junction.
Immunohistochemistry experiments
Immunohistochemistry experiments were performed
using methods described previously [12]. All primary
antibodies were obtained from Santa Cruz Biotechnology
unless indicated. Sections were deparaffinized, rehy-
drated, and immersed in 3% H2O2  and antigen was
unmasked using either heat-induced epitope retrieval (10
mmol/L sodium citrate, pH 6.0 at 90°C for 5 min) or
microwave for 5 minutes. Blocking was done using 5%
goat serum at room temperature. After blocking, the
appropriate primary antibody was added and incubated
in 4°C overnight. The slides were washed in PBS, incu-
bated with the goat anti-mouse biotin conjugate (Sigma
Co, St. Louis, MO), then with extravidin-peroxidase
(Sigma) and counterstained with either hematoxylin or
1% methylgreen.
The following primary antibodies were selected to evalu-
ate chondrocyte proliferation: [a]histone-4 at 5 μg/ml, [b]
mammalian target of rapamycin (mTOR) at 4 μg/ml, [c] par-
athyroid hormone/parathyroid hormone related-peptide (PTH/
PTHrP) at 4.4 μg/ml (Upstate Biotechnology), [d] Growth
Hormone Receptor (GHR) at 4 μg/ml, and [e] type II collagen
(Col2a) at 4 μg/ml. Chondrocyte maturation was assessed
using: [a] Indian Hedgehog (Ihh) at 10 μg/ml, [b] Insulin-
like Growth Factor I (IGF-I) at 10 μg/ml (Upstate Biotech-
nology], [c] Insulin Growth Factor Binding Protein (IGFBP3)
at 10 μg/ml, [d] p57Kip2 at 4 μg/ml, [e] p21Waf1/Cip1 at 8 μg/
ml, [f] type × collagen (Col10a) at 8 μg/ml, and [g] Bone
Morphogenetic Protein-7 (BMP-7) at 5 μg/ml.
Osteo/chondroclastic activity was evaluated using Receptor
Activator for Nuclear Factor Kappa β Ligand (RANKL) at 6
μg/ml and Osteoprotegerin (OPG) at 5 μg/ml. Histochemi-
cal staining for tartrate-resistant acid phosphatase (TRAP)
and  gelatinase B/MMP-9 were done using methods
reported previously [9].
For quantification of the protein expression, slides were
viewed at 65× by bright field microscopy and images were
captured using a CCD video camera control unit. Approx-
imately 50 to 60 cell profiles (chondrocytes) were
assessed in the layer of the growth plate where the protein
expression was counted and expressed as percentage of
the labeled cells over the total number of cells where the
expression is localized and the number of positive cells
was counted and expressed as percentage of the labeled
cells over the total number of cells where the expression is
localized (Labeling Index) [12].
Histochemical staining for tartrate-resistant acid phos-
phatase (TRAP) was done using methods previously
reported on sections of bone prepared and mounted in
the same manner as for in-situ hybridization and immu-
nohistochemistry experiments [9]. To quantify tartrate
resistant acid phosphatase (TRAP), the number of TRAP
positive cells in the chondro-osseous junction was
counted and expressed as number of cells per area meas-
ured in the chondro-osseous junction and in the nearby
primary spongiosa [9].BMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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Statistical analysis
All results are expressed as mean values ± 1 SD. Data were
evaluated by one-way ANOVA and comparisons among
groups were done using Bonferroni/DUNN post-hoc tests
using the StatView®  statistical software (SAS Institute,
Cary, NC). The Pearson product moment correlation coef-
ficient was used to evaluate the relationship between two
numerical variables. For all statistical tests, probability
values less than 5% were considered to be significant.
Results
Measurements of body weight, body length and food 
intake
Gain in body weight was 14 percent and 19 percent higher
in Control compared to Rapamycin groups after 2 and 4
weeks of treatment (Table 1). Body length measurements
declined by 11 percent and 19 percent after 2 and 4 weeks
of Rapamycin (Table 1). Tibial length measurements were
6 to 10 percent shorter in both Rapamycin groups (Table
1). Although the total caloric intake was similar in
Rapamycin and Control groups, the calculated food effi-
ciency ratio was higher with rapamycin which may sug-
gest that a higher caloric intake may be required for
growth or there may be dysregulation in the utilization of
calories during rapamycin administration (Table 1).
Serum biochemical parameters
Serum parathyroid hormone (PTH) and phosphate levels
declined after 4 weeks of rapamycin (Table 2). Serum cal-
cium levels were similar in all groups (Table 2). Serum
creatinine levels were comparable in Rapamycin and Con-
trol groups at the end of 2 weeks and 4 weeks of treatment
(Table 2). Serum IGF-I levels were 18 percent lower in
Rapamycin and Control at the end of 2 weeks (Table 2).
Growth plate measurements
Despite shorter body and tibial length, the growth plate
was 26 percent wider compared to Control after two
weeks of rapamycin accompanied by an increase in the
area occupied by hypertrophic chondrocytes and a
decrease in the proliferative zone (Figure 1). At the end of
4 weeks, the growth plate width was similar between the
Rapamycin and the Control, 475 ± 89 μm and 509 ± 35
μm, p = NS (Figure 1). There were no obvious abnormal-
ities in the columnar architecture of the growth plate car-
tilage (Figure 1).
In-situ hybridization and immunohistochemistry studies
Rapamycin inhibits the mammalian target of rapamycin
(mTOR) which is crucial to cell cycle progression and thus,
may lower chondrocyte proliferation. In the current study,
we evaluated whether the shorter bone growth was prima-
rily due to a decline in chondrocyte proliferation. The pro-
tein expression of selected markers associated with
chondrocyte proliferation was assessed including PTH/
PTHrP receptor, histone-4, mTOR, growth hormone receptor
and type II collagen (Col2a1). In the growth plate, Col2a1 is
the most abundant collagen which is expressed in all lay-
ers of chondrocytes. Rapamycin lowered Col2a1 expres-
sion by 40 percent compared to Control at 2 weeks
particularly in the hypertrophic chondrocytes (Figure 2A).
After 4 weeks of Rapamycin, Col2a1 staining was compa-
rable to Control (Figure 2A).
Histone-4 localized to the proliferating chondrocytes and
declined by 60 percent after 2 weeks of rapamycin com-
pared to Control; 28 ± 11 percent versus 71 ± 10 percent
(Figure 2B), p < 0.001. Similar to Col2a1 expression, his-
tone-4 slightly increased after 4 weeks of rapamycin but
remained 40 percent lower than Control (Figure 2B), p =
Table 1: Morphometric measurements, food intake and food efficiency ratio (FER) in all groups
Parameters 2 weeks 4 weeks
Rapamycin, N = 6 Control, N = 6 Rapamycin, N = 7 Control, N = 7
Change in body weighta (grams) 63 ± 6d, e 73 ± 8d 128 ± 7f 159 ± 11
Change in body lengtha (centimeters) 7.6 ± 0.6d, e 8.6 ± 0.5d 13 ± 1.2f 16 ± 0.7
Tibial Lengthb (centimeters) 3.0 ± 0.05d, e 3.2 ± 0.05d 3.4 ± 0.09f 3.7 ± 0.15
Total food intakeb (grams) 185 ± 1.8 183 ± 5.3 390 ± 32 410 ± 4.8
Food Efficiency Ratioc (FER) 3.0 ± 0.5e 2.6 ± 0.6 3.0 ± 0.5f 2.6 ± 0.3
aDifference between measurements at 2 or 4 weeks and baseline
bObtained at the time of sacrifice
cTotal food consumed/weight gain during the study period
dp < 0.0001, 2 weeks versus 4 weeks (same group)
ep < 0.001, rapamycin versus control at 2 weeks
fp < 0.0001, rapamycin versus control at 4 weeksBMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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Table 2: Biochemical parameters in all groups
Serum Parameters 2 weeks 4 weeks
Rapamycin, N = 6 Control, N = 6 Rapamycin, N = 7 Control, N = 7
Intact PTHa (pg/mL) 40 ± 22 68 ± 34 32 ± 21c 90 ± 37
Calciuma (mg/dL) 10 ± 0.6 10 ± 0.4 9.8 ± 0.1 10 ± 0.1
Phosphorusa (mg/dL) 12 ± 0.2b 12 ± 0.5 10 ± 0.5 11 ± 0.7
Creatininea (mg/dL) 0.2 ± 0.04b 0.2 ± 0.03b 0.3 ± 0.04 0.3 ± 0.07
IGF-Ia (ng/mL) 708 ± 222b 867 ± 180b 1028 ± 256c 1318 ± 297
aObtained at the time of sacrifice
bp < 0.003, 2 weeks versus 4 weeks (same group)
cp < 0.006, rapamycin versus control (4 weeks)
The upper panels show the measurements of the total growth plate (black square), proliferative zone (white square) and  hypertrophic zone (gray square) after 2 weeks (left panel) and after 4 weeks (right panel) in Rapamycin and Control groups,  expressed in micrometers Figure 1
The upper panels show the measurements of the total growth plate (black square), proliferative zone (white 
square) and hypertrophic zone (gray square) after 2 weeks (left panel) and after 4 weeks (right panel) in 
Rapamycin and Control groups, expressed in micrometers. The lower panels show the corresponding photomicro-
graphs of the growth plate cartilage in all groups, 30×. Note the increase in the zone occupied by hypertrophic chondrocytes 
in the 2 weeks Rapamycin group (left panel). The solid brackets denote the layer of proliferating chondrocytes and the dashed 
brackets indicate the hypertrophic zone; ap < 0.001 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.002 Rapamycin (2 
weeks) vs Rapamycin (4 weeks).BMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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< 0.05. Histone and DNA synthesis are initiated at the
beginning of S phase of the cell cycle by cyclin/cdk2 activ-
ity. Cyclin expression was not evaluated in the current
experiment, but our previous results have shown that his-
tone-4  positively correlated with proliferating nuclear
staining (PCNA) which is specific to proliferating cells
[13].
mTOR expression was demonstrated in both proliferating
and upper hypertrophic chondrocytes and declined after 2
and 4 weeks of rapamycin (Figure 2C).
PTH/PTHrP  and  Ihh  are essential in the regulation of
chondrocyte proliferation and chondrocyte differentia-
tion in the growth plate cartilage. A feedback loop exists
between  PTHrP  and  Ihh  which controls the pace of
chondrocyte proliferation [14]. Acceleration of chondro-
cyte differentiation and premature ossification in the
growth plate have been reported in PTH/PTHrP  null
mouse [15,16]. Chondrocyte proliferation declined and
the area occupied by hypertrophic chondrocytes increased
in targeted deletion of Ihh [14]. After 2 weeks of rapamy-
cin, PTH/PTHrP which localized to the lower proliferating
The panels on the left show representative photomicrographs of type II collagen protein expression (2A) in the proliferating and  hypertrophic chondrocytes, 20× (denoted by the purple color and brackets); ap < 0.003 Rapamycin (2 weeks) vs Control (2  weeks) Figure 2
The panels on the left show representative photomicrographs of type II collagen protein expression (2A) in the 
proliferating and hypertrophic chondrocytes, 20× (denoted by the purple color and brackets); ap < 0.003 
Rapamycin (2 weeks) vs Control (2 weeks). Histone-4 protein expression (2B, denoted by arrows and brown color), 50×; 
ap < 0.001 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.05 Rapamycin (2 weeks) vs Rapamycin (4 weeks); cp < 0.04 
Rapamycin (4 weeks) vs Control (4 weeks). mTOR protein expression (2C, denoted by arrows and brown color), 50×; ap < 
0.004 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.001 Rapamycin (4 weeks) vs Control (4 weeks). The panels on the 
right show the quantification of the protein expression for type II collagen (upper panel); histone-4 (middle panel); and mTOR 
(lower panel) after 2 weeks and 4 weeks in Rapamycin and Control groups expressed as number of labeled cells to the total 
number of cells in the appropriate zone (Labeling Index).
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2A.  Type II collagen 2A.  Type II collagen
2B. Histone-4
2B. Histone-4
2C. mTOR 2C. mTORBMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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and upper hypertrophic chondrocytes declined by 30 per-
cent compared to Control. In contrast, Ihh expression con-
fined mostly to the hypertrophic chondrocytes increased
approximately 2-fold after 2 weeks of rapamycin (Figure
3A). At the end of 4 weeks, PTH/PTHrP and Ihh expression
were comparable to the Control group (Figure 3A and
3B). The current results suggest that the widening of the
hypertrophic zone and decrease in the proliferative zone
may be due in part to enhancement of Ihh and downreg-
ulation of PTH/PTHrP.
Other markers used in the study to assess chondrocyte
maturation include: IGF-I protein, IGF-I binding protein-3
(IGFBP3), type × collagen and bone morphogenetic-7 (BMP-
7).
The protein expression of IGF-I which was restricted to the
hypertrophic chondrocytes decreased after 2 weeks of
rapamycin compared to Control (Figure 4A). In agree-
ment with other published studies, IGF-I staining was 20
percent lower in the 2 weeks Control animals compared
to 4 weeks Control (Figure 4A). IGF-II and not IGF-I has
been demonstrated to be more abundant in younger ani-
mals and that IGF-I may be associated with chondrocyte
hypertrophy and mineralization [17]. The expression of
IGF-II was not assessed in the current study.
The panels on the left show representative photomicrographs of PTH/PTHrP protein expression (3A) in the lower proliferating  and upper hypertrophic chondrocytes, 50× (denoted by the purple color and arrows); ap < 0.004 Rapamycin (2 weeks) vs  Rapamycin (4 weeks) Figure 3
The panels on the left show representative photomicrographs of PTH/PTHrP protein expression (3A) in the 
lower proliferating and upper hypertrophic chondrocytes, 50× (denoted by the purple color and arrows); ap < 
0.004 Rapamycin (2 weeks) vs Rapamycin (4 weeks). Indian hedgehog protein expression in the lower proliferating and 
upper hypertrophic chondrocytes (3B, denoted by arrows and brown color), 50×; ap < 0.02 Rapamycin (2 weeks) vs Control 
(2 weeks); bp < 0.0001 Rapamycin (2 weeks) vs Rapamycin (4 weeks). The panels on the right show the quantification of the 
protein expression for PTH/PTHrP (upper panel); and Indian hedgehog (lower panel) after 2 weeks and 4 weeks in Rapamycin 
and Control groups expressed as number of labeled cells to the total number of cells in the appropriate zone (Labeling Index).BMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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IGFBP3 protein expression was localized to the proliferat-
ing and upper hypertrophic chondrocytes in both 2 weeks
and 4 weeks Rapamycin and Control groups (Figure 4B).
Two weeks of rapamycin downregulated IGFBP3 by 53
percent compared to the Control group, and by 44 percent
compared to the 4 weeks Rapamycin group (Figure 4b).
The changes in IGFBP3 were similar to the changes in IGF-
I protein expression.
Type × collagen (col10a) is a marker of chondrocyte matu-
ration and solely localized to the hypertrophic chondro-
cytes. Although the width of the zone occupied by the
hypertrophic chondrocytes increased with rapamycin,
col10a expression declined 2-fold after 2 and 4 weeks of
treatment compared to Control groups (Figure 4C).
It has been demonstrated that the proliferative actions of
PTHrP  may be mediated by downregulation of cyclin
kinase inhibitors p57Kip2 and p27Kip1 [18]. In the current
study, there was a 20 to 30 percent reduction in p57Kip2
staining in the hypertrophic chondrocytes of both
Rapamycin groups (2 and 4 weeks) compared to Control
The panels on the left show representative photomicrographs of IGF-I protein expression (4A), 50× (denoted by the brown  color and arrows); ap < 0.04 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.03 Rapamycin (2 weeks) vs Rapamycin (4  weeks); cp < 0.03 Control (2 weeks) vs Control (4 weeks) Figure 4
The panels on the left show representative photomicrographs of IGF-I protein expression (4A), 50× (denoted 
by the brown color and arrows); ap < 0.04 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.03 Rapamycin (2 
weeks) vs Rapamycin (4 weeks); cp < 0.03 Control (2 weeks) vs Control (4 weeks). IGFBP3 protein expression (4B, 
denoted by arrows and brown color), 50×; ap < 0.002 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.03 Rapamycin (2 
weeks) vs Rapamycin (4 weeks). Type × collagen (col10a) protein expression localized only to the hypertrophic chondrocytes 
(4C, denoted by purple color and brackets), 20×; ap < 0.005 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.02 Rapamycin 
(4 weeks) vs Control (4 weeks). The panels on the right show the quantification of the protein expression for IGF-I (upper 
panel); IGFBP3 (middle panel); and type × collagen (lower panel) after 2 weeks and 4 weeks in Rapamycin and Control groups 
expressed as number of labeled cells to the total number of cells in the appropriate zone (Labeling Index).
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                         4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
4A.  IGF-I 4A.  IGF-I
4B.  IGFBP3 4B.  IGFBP3
4C.  Type X Collagen 4C.  Type X CollagenBMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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accompanied by lower histone-4 expression (Figure 5A).
There were no changes in p21Cip-1/SDI-1/WAF-1 expression in
all groups (Figure 5B). The expression of bone morphoge-
netic protein-7 (BMP-7) and growth hormone receptor did
not differ among groups (pictures not included).
Vascular invasion and cartilage resorption are crucial steps
in endochondral bone growth. Rapamycin did not affect
the expression of gelatinase B or matrix metalloproteinase-9
(MMP-9) mRNA after 2 or 4 weeks compared to the Con-
trol groups, although the expression was relatively higher
in the growth plate of younger animals (Figure 6A).
Receptor activator of nuclear factor-kappa β ligand (RANKL)
and osteoprotegerin (OPG) participate in the regulation of
osteo/chondroclastogenesis. We have previously demon-
strated that RANKL and OPG expression were localized to
the hypertrophic chondrocytes and the ratio between
RANKL:OPG has been used to estimate the presence of
osteo/chondroclast differentiation [19]. There was a 40
percent decrease in RANKL expression after 2 weeks of
rapamycin compared to Control (Figure 6B); this change
was not evident after 4 weeks of rapamycin (Figure 6B).
Since OPG expression did not change in all groups (Figure
6C), the RANKL:OPG ratio was lower in the 2 week
rapamycin group which may suggest decline in osteo/
chondroclastogenesis (Figure 6C).
Vascular endothelial growth factor (VEGF) was demon-
strated in the mature hypertrophic chondrocytes and the
expression was 30 percent less after 2 and 4 weeks of
rapamycin compared to control (Figure 7A). Histochemi-
cal staining for tartrate resistant acid phosphatase (TRAP)
was considerably reduced in both rapamycin groups (Fig-
ure 7B).
Discussion
Rapamycin is a potent immunosuppressant which can
inhibit endochondral bone growth in young rats. Our
study suggests that rapamycin may decrease chondrocyte
proliferation, alter maturation of hypertrophic chondro-
cytes, delay vascular invasion and reduce TRAP activity in
the chondro-osseous junction of the growth plate carti-
lage.
The panels on the left show representative photomicrographs of p57Kip2 protein expression in the hypertrophic chondrocytes  (5A, denoted by arrows and brown color), 50×; ap < 0.05 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.05 Rapamycin (4  weeks) vs Control (4 weeks) Figure 5
The panels on the left show representative photomicrographs of p57Kip2 protein expression in the hypertrophic 
chondrocytes (5A, denoted by arrows and brown color), 50×; ap < 0.05 Rapamycin (2 weeks) vs Control (2 
weeks); bp < 0.05 Rapamycin (4 weeks) vs Control (4 weeks). p21Cip-1/SDI-1/WAF-1 protein expression localized only to the 
terminal hypertrophic chondrocytes (5B, denoted by arrows and brown color), 50×. The panels on the right show the quanti-
fication of the protein expression for p57Kip2 (upper panel); and p21Cip-1/SDI-1/WAF-1 (lower panel) after 2 weeks and 4 weeks in 
Rapamycin and Control groups expressed as number of labeled cells to the total number of cells in the appropriate zone (Labe-
ling Index).BMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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Currently, there are no available studies that have evalu-
ated the effects of rapamycin in young and growing chil-
dren. The implications of our findings on linear growth
need further evaluation in young children who are main-
tained on long-term immunosuppressant treatment with
rapamycin. The rapamycin dose used in the current study
was higher than the currently prescribed amount in pedi-
atric patients, but similar doses were previously utilized in
published animal studies [3,4].
The adverse effects of rapamycin on the growth plate were
more evident in younger animals. It was expected that the
smaller animals which were treated with 2 weeks of
rapamycin will have smaller growth plate cartilage how-
ever, our findings demonstrated an increase rather than
decrease in the total growth plate with widening of the
layer occupied by hypertrophic chondrocytes. Although
there was a significant increase in hypertrophic zone, the
columnar architecture was preserved. The enlargement of
the hypertrophic zone may be due in part, to a reduction
in the number of proliferating chondrocytes, lower carti-
lage resorption in the chondro-osseous junction due to a
decline in TRAP and there may be a delay in vascular inva-
sion. Although the changes in the growth plate which
were evident after 2 weeks improved at the end of 4 weeks
of rapamycin, body length and tibial length measure-
The panels on the left show representative photomicrographs of gelatinase B/MMP-9 mRNA expression in the chondro- osseous junction (6A), denoted by the black color and arrows, 20×); ap < 0.02 Rapamycin (2 weeks) vs Rapamycin (4 weeks) Figure 6
The panels on the left show representative photomicrographs of gelatinase B/MMP-9 mRNA expression in the 
chondro-osseous junction (6A), denoted by the black color and arrows, 20×); ap < 0.02 Rapamycin (2 weeks) vs 
Rapamycin (4 weeks). RANKL protein expression in the hypertrophic chondrocytes (6B, denoted by arrows and brown 
color), 50×; ap < 0.008 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.002 Rapamycin (2 weeks) vs Rapamycin (4 weeks). 
OPG protein expression localized to the hypertrophic chondrocytes (6C, denoted by arrows and brown color), 50×. The pan-
els on the right show the quantification of the protein expression for gelatinase B/MMP-9 (upper panel); RANKL (middle panel); 
and OPG (lower panel) after 2 weeks and 4 weeks in Rapamycin and Control groups expressed as number of labeled cells to 
the total number of cells in the appropriate zone (Labeling Index).
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks            4 weeks            2 weeks            4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
2 weeks                          4 weeks                 2 weeks                       4 weeks
Rapamycin Control
6A. Gelatinase  B 6A. Gelatinase  B
6B.  RANKL 6B.  RANKL
6C. OPG 6C. OPGBMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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ments remained short. Longer follow-up needs to be done
in future studies to assess whether catch-up growth will
occur in the rapamycin treated animals.
The immunosuppressive effects of rapamycin are based
on its ability to inhibit cell cycle progression from G1 to S
phase and hinder DNA synthesis by restraining the phos-
phorylation of p70S6 kinase leading to inactivation of the
mammalian target of rapamycin (mTOR) [20,21]. The
mammalian target of rapamycin (mTOR) integrates signals
from nutrition and growth factors to coordinate cell
growth and cell proliferation [22]. Rapamycin can also
decrease cyclin D and cyclin E protein expression includ-
ing downstream effectors involved in cell cycle progres-
sion [23]. In the present study, chondrocyte proliferation
assessed by histone-4 and mTOR expression was signifi-
cantly decreased. Although the markers of chondrocyte
proliferation improved in older rats treated with rapamy-
cin, bone length remained short after 7 weeks of study
period. These findings suggest that the inhibitory effects of
rapamycin on chondrocyte proliferation may be more sig-
nificant in young animals due to rapid growth which may
be a concern during long-term rapamycin therapy in
young pediatric patients. The reduction in histone-4 and
mTOR was also accompanied by a decline in type II (col2a)
collagen expression, another marker of chondrocyte pro-
liferation and important in the extracellular matrix sup-
port of chondrocytes.
The present study showed a downregulation of PTH/
PTHrP accompanied by enhancement of Ihh after 2 weeks
of rapamycin; such changes were not significant at the end
of 4 weeks. The PTH/PTHrP  and Indian hedgehog (Ihh)
feedback loop plays an important role in chondrocyte
proliferation and differentiation. The increase in the zone
occupied by the hypertrophic chondrocytes may be a
combination of the decline in PTH/PTHrP and upregula-
tion of Ihh expression. Our current findings show that the
downregulation of PTH/PTHrP during rapamycin therapy
was not due to the enhancement of cyclin kinase inhibitor
p57Kip2.
Chondrocyte proliferation, chondrocyte maturation and
apoptosis of the terminal hypertrophic chondrocytes
The panels on the left show representative photomicrographs of VEGF mRNA expression in the hypertrophic chondrocytes  (7A), denoted by the black color and arrows, 50×; ap < 0.03 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.03 Rapamycin  (4 weeks) vs Control (4 weeks) Figure 7
The panels on the left show representative photomicrographs of VEGF mRNA expression in the hypertrophic 
chondrocytes (7A), denoted by the black color and arrows, 50×; ap < 0.03 Rapamycin (2 weeks) vs Control (2 
weeks); bp < 0.03 Rapamycin (4 weeks) vs Control (4 weeks). TRAP positive chondro/osteoclasts (7B), denoted by 
arrows and red color, 50×; ap < 0.01 Rapamycin (2 weeks) vs Control (2 weeks); bp < 0.03 Rapamycin (4 weeks) vs Control (4 
weeks). The panels on the right show the quantification of the protein expression for VEGF (upper panel) and TRAP (lower 
panel) after 2 weeks and 4 weeks in Rapamycin and Control groups expressed as number of labeled cells to the total number 
of cells in the appropriate zone (Labeling Index).BMC Pediatrics 2009, 9:3 http://www.biomedcentral.com/1471-2431/9/3
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must be precisely coordinated and any delay in each stage
can lead to shorter bone growth as shown in the current
experiment. Markers of chondrocyte differentiation that
were evaluated in the current paper including IGF-I and
IGF binding protein-3 were downregulated after 2 weeks
but improved at the end of 4 weeks. Only type × collagen
(col10) and p57Kip2 expression remained low after 4 weeks
of rapamycin treatment. Type × collagen has been demon-
strated to play an essential role in the initiation of matrix
mineralization in the chondro-osseous junction and in
the maintenance of progenitor cells for osteo/chondro-
genesis and hematopoiesis [24]. The alterations in prolif-
eration and differentiation of chondrocytes in the growth
plate during rapamycin therapy may delay mineralization
and vascularization in the appendicular skeleton and con-
sequently, may affect the production of bone marrow pro-
genitor cells. These findings will require further
evaluation.
Alvarez and colleagues have demonstrated that 14 days of
intraperitoneal rapamycin led to smaller tibial bones
associated with decreased body weight and lower food
efficiency ratio [4]. Our findings agree with previous
reports and may suggest that during rapamycin treatment,
animals may require higher amount of calories per day in
order to grow. Since mTOR is an important modulator of
insulin-mediated glucose metabolism, rapamycin may
exert adverse effects on the absorption of nutrients [25].
When given orally as in the current study, rapamycin may
lower intestinal absorption of glucose, amino acids and
linoleic acids by decreasing the area of the absorptive
intestinal mucosa [10].
Rapamycin has been studied as an effective treatment for
cancer not only due to its anti-proliferative actions but for
its anti-angiogenic properties [26]. Our current findings
showed a significant downregulation of vascular endothe-
lial growth factor expression in the hypertrophic chondro-
cytes of animals treated with rapamycin. Our findings are
in agreement with previous reports by Alvarez-Garcia and
coworkers [4]. Although there were no changes in gelati-
nase B/MMP-9 mRNA expression in the chondro-osseous
junction, there was a considerable reduction in the
number of TRAP positive chondro/osteoclasts suggesting
that cartilage resorption may be altered by rapamycin. The
delay in cartilage resorption and changes in chondro/oste-
oclast function may be due to the reduction in RANKL
expression as shown in the present experiment and by
other investigators [6]. There were no changes in osteopro-
tegerin (OPG) staining so RANKL/OPG  ratio was lower
compared to Control. The decrease in RANKL/OPG ratio
may reflect a decrease in chondro/osteoclast recruitment
and differentiation.
Conclusion
Rapamycin is a novel and powerful immunosuppressant
widely used in pediatric renal transplant recipients to
maintain the allograft. We have shown in the current
study that rapamycin can inhibit endochondral bone
growth in a rapidly growing young animal. The shorter
bone growth may be due in part, to the decline in
chondrocyte proliferation, enhancement of chondrocyte
maturation, and alterations in cartilage resorption and
vascularization. Our findings have also demonstrated that
the 2 week effects of rapamycin on chondrocyte prolifera-
tion, chondrocyte maturation and vascular invasion may
improve to near normal if rapamycin is administered con-
tinuously as the animal matures although, no catch-up
growth was demonstrated. The results in the current study
may be limited by the semi-quantitative results obtained
using in-situ and immunohistochemistry methods, so
future experiments should be done using quantitative
proteomic and genomic techniques. In addition, clinical
studies are needed to assess whether long-term therapy
with rapamycin can affect linear growth in young pediat-
ric patients.
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